Ranibizumab and the eye

Noble, Jason; Chaudhary, Varun
April 2011
CMAJ: Canadian Medical Association Journal;4/19/2011, Vol. 183 Issue 7, p822
Academic Journal
The article offers information on the use of the VEGF-A inhibitor ranibizumab as treatment for wet age-related macular degeneration. It states that several large randomized controlled trials have been conducted to examine the efficacy and safety of ranibizumab. It also says that systemic adverse effects after the injection of ranibizumab are rare occurrences, however, patients who suffered from these effects should be referred for ophthalmic evaluation.


Related Articles

  • Implant extends lasting effects for treatment of chronic DME. Kiernan, Daniel // Ophthalmology Times;Sep2015, Vol. 40 Issue 15, p44 

    The article focuses on the effectiveness of anti-vascular endothelial growth factor in the treatment of diabetic macular edema (DME). Topics mentioned include improved outcomes compared to focal laser photocoagulation which was the previous standard of care, decreased levels of anti-inflammatory...

  • CABERNET study falls short of efficacy benchmarks at 2 years. Hasson, Matt // Ocular Surgery News;4/25/2013, Vol. 31 Issue 8, p55 

    The article discusses the CABERNET research led by ophthalmologist Pravin U. Dugel that reveals that epimacular brachytherapy failed to achieve two-year efficacy endpoints in treating wet age-related macular degeneration in treatment-naive patients. By far, the use of epimacular brachytherapy in...

  • Endophthalmitis following intravitreal anti-VEGF injections in ambulatory surgical centre facility: incidence, management and outcome. Mithal, Kopal; Mathai, Annie; Pathengay, Avinash; Jalali, Subhadra; Relhan, Nidhi; Reddy Motukupally, Swapna; Sharma, Savitri; Das, Taraprasad // British Journal of Ophthalmology;Dec2013, Vol. 97 Issue 12, p1609 

    A letter to the editor is presented which is concerned with research which investigated the incidence, management and outcome of cases of endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injections in an ambulatory surgical centre facility.

  • First injections can predict anti-VEGF success in DME. Harrison, Laird // Ophthalmology Times;Jan2016, Vol. 41 Issue 1, p29 

    The article reviews research indicating that clinicians can predict a patient's long-term response to anti-vascular endothelial growth factor (VEGF) treatment of diabetic macular edema (DME) after three injections. Topics include researchers Doctor Pravin Dugel and colleagues conducting a post...

  • Breakthrough studies revive discussion of anti-VEGF treatment regimens for AMD.  // Ocular Surgery News Europe;Feb2012, Vol. 23 Issue 2, p1 

    The article tackles the retrospective observational study LUMIERE which examined the current practices of ranibizumab treatment in France which were presented at the 2011 Association for Research in Vision and Ophthalmology meeting. The study has reportedly revived discussion of anti-vascular...

  • Intravitreal bevacizumab injection for peripheral exudative hemorrhagic chorioretinopathy. Alforja, María; Sabater, Noelia; Giralt, Joan; Adán, Alfredo; Pelegrín, Laura; Casaroli-Marano, Ricardo // Japanese Journal of Ophthalmology;Jul2011, Vol. 55 Issue 4, p425 

    A case study is presented of a woman who was referred for suspicion of a choroidal malignant melanoma oculus dexter (OD) with decreasing visual acuity. A diagnosis of peripheral exudative hemorrhagic chorioretinopathy (PECHR) was given. The use of an intravitreal injection of bevacizumab was...

  • Eylea Snares Second Approval. Shechtman, Diana L.; Karpecki, Paul M. // Review of Optometry;12/15/2012, Vol. 149 Issue 12, p67 

    The article discusses the drug approval of the anti-vascular endothelial growth factor (VEGF) agent, Eylea for the treatment of wet age related macular degeneration (AMD) and macular edema secondary to retinal vein occlusion. It further compares the drug with another ant wet AMD drug, Lucentis....

  • Characteristics of fine vascular network pattern associated with recurrence of polypoidal choroidal vasculopathy. Oishi, A.; Mandai, M.; Kimakura, M.; Nishida, A.; Kurimoto, Y. // Eye;Aug2011, Vol. 25 Issue 8, p1020 

    ObjectiveTo characterize an irregular capillary-like structure in the vascular network of eyes with polypoidal choroidal vasculopathy (PCV), and to determine whether its presence after photodynamic therapy (PDT) can be used to predict the clinical course of PCV.MethodsWe reviewed the clinical...

  • Researcher: Data inconclusive on as-needed anti-VEGF therapy.  // Ocular Surgery News;11/25/2009, Vol. 27 Issue 22, p21 

    The article reveals the paucity of evidence supporting the idea that as-needed anti-vascular endothelial growth factor (VEGF) therapy is either superior or inferior to monthly dosing in the treatment age-related macular degeneration, according to ophthalmologist Carl D. Regillo. Dosing...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics